PTC Therapeutics, Inc. Gain (Loss) on Extinguishment of Debt
PTC Therapeutics, Inc. (PTCT) reported Gain (Loss) on Extinguishment of Debt of -$137.56 million for the 12-month period ending 2023-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2026-02-19
- PTC Therapeutics, Inc. gain (loss) on extinguishment of debt for the quarter ending 2013-12-31 was $0.00.
- PTC Therapeutics, Inc. gain (loss) on extinguishment of debt for the quarter ending 2013-09-30 was -$129.96K.
- PTC Therapeutics, Inc. gain (loss) on extinguishment of debt for fiscal 2023 was -$137.56M.
- PTC Therapeutics, Inc. gain (loss) on extinguishment of debt for fiscal 2013 was -$130.00K.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 9 month as first filed | Gain (Loss) on Extinguishment of Debt 12 month | Gain (Loss) on Extinguishment of Debt 12 month as first filed |
|---|---|---|---|---|---|---|
| 2023-12-31 | -$137.56M 10-K · filed 2026-02-19 | |||||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | -$129.96K derived: sum of 2 quarters · filed 2016-02-29 | -$130.00K 10-K · filed 2016-02-29 | -$129.96K 10-K · filed 2014-03-06 | ||
| 2013-09-30 | -$129.96K 10-Q · filed 2013-11-14 | -$130.00K 10-Q · filed 2014-11-06 | -$129.96K 10-Q · filed 2013-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |